RxSight Inc. (RXST)
RxSight Statistics
Share Statistics
RxSight has 40.49M shares outstanding. The number of shares has increased by 3.87% in one year.
Shares Outstanding | 40.49M |
Shares Change (YoY) | 3.87% |
Shares Change (QoQ) | 0.46% |
Owned by Institutions (%) | 88.75% |
Shares Floating | 38.39M |
Failed to Deliver (FTD) Shares | 47 |
FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 2.28M, so 5.66% of the outstanding shares have been sold short.
Short Interest | 2.28M |
Short % of Shares Out | 5.66% |
Short % of Float | 5.96% |
Short Ratio (days to cover) | 2.91 |
Valuation Ratios
The PE ratio is -48.67 and the forward PE ratio is 236.09. RxSight's PEG ratio is 0.98.
PE Ratio | -48.67 |
Forward PE | 236.09 |
PS Ratio | 9.55 |
Forward PS | 2.2 |
PB Ratio | 4.75 |
P/FCF Ratio | -59.69 |
PEG Ratio | 0.98 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for RxSight.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.36, with a Debt / Equity ratio of 0.04.
Current Ratio | 11.36 |
Quick Ratio | 10.5 |
Debt / Equity | 0.04 |
Debt / EBITDA | -0.52 |
Debt / FCF | -0.55 |
Interest Coverage | -1755.14 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $280.98K |
Profits Per Employee | $-55.13K |
Employee Count | 498 |
Asset Turnover | 0.44 |
Inventory Turnover | 1.86 |
Taxes
Income Tax | 50K |
Effective Tax Rate | -0.18% |
Stock Price Statistics
The stock price has increased by -68.44% in the last 52 weeks. The beta is 1.22, so RxSight's price volatility has been higher than the market average.
Beta | 1.22 |
52-Week Price Change | -68.44% |
50-Day Moving Average | 28.49 |
200-Day Moving Average | 42.65 |
Relative Strength Index (RSI) | 20.92 |
Average Volume (20 Days) | 615.29K |
Income Statement
In the last 12 months, RxSight had revenue of 139.93M and earned -27.45M in profits. Earnings per share was -0.71.
Revenue | 139.93M |
Gross Profit | 98.94M |
Operating Income | -36.86M |
Net Income | -27.45M |
EBITDA | -23.76M |
EBIT | -27.38M |
Earnings Per Share (EPS) | -0.71 |
Balance Sheet
The company has 16.71M in cash and 12.3M in debt, giving a net cash position of 4.41M.
Cash & Cash Equivalents | 16.71M |
Total Debt | 12.3M |
Net Cash | 4.41M |
Retained Earnings | -622.1M |
Total Assets | 318.56M |
Working Capital | 267.95M |
Cash Flow
In the last 12 months, operating cash flow was -16.95M and capital expenditures -5.44M, giving a free cash flow of -22.39M.
Operating Cash Flow | -16.95M |
Capital Expenditures | -5.44M |
Free Cash Flow | -22.39M |
FCF Per Share | -0.58 |
Margins
Gross margin is 70.71%, with operating and profit margins of -26.34% and -19.62%.
Gross Margin | 70.71% |
Operating Margin | -26.34% |
Pretax Margin | -19.59% |
Profit Margin | -19.62% |
EBITDA Margin | -16.98% |
EBIT Margin | -26.34% |
FCF Margin | -16% |
Dividends & Yields
RXST does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for RXST is $43, which is 162% higher than the current price. The consensus rating is "Buy".
Price Target | $43 |
Price Target Difference | 162% |
Analyst Consensus | Buy |
Analyst Count | 9 |
Scores
Altman Z-Score | 14.88 |
Piotroski F-Score | 4 |